Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis

Published:2016 Issue:5 Volume:55 Page:443-448
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Bando Masashi¹,Yamauchi Hiroyoshi¹,Ogura Takashi²,Taniguchi Hiroyuki³,Watanabe Kentaro⁴,Azuma Arata⁵,Homma Sakae⁶,Sugiyama Yukihiko¹,The Japan Pirfenidone Clinical Study Group

Affiliation:

1. Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Japan

2. Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan

3. Department of Respiratory Medicine and Allergy, Tosei General Hospital, Japan

4. Department of Respiratory Medicine, Fukuoka University School of Medicine, Japan

5. Division of Pulmonary Medicine, Infection and Oncology, Nippon Medical School, Japan

6. Department of Respiratory Medicine, Toho University Omori Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/55/5/55_55.5272/_pdf

Reference13 articles.

1. 1. Raghu G, Collard HR, Egan JJ, et al; on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.

2. 2. Diagnosis and treatment guidance of idiopathic interstitial pneumonia. 2nd ed. The Japanese Respiratory Society Diagnosis and Treatment Guidelines Construction Committee, Ed. Nankodo, Tokyo, 2011 (in Japanese).

3. 3. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 6: 107-114, 2012.

4. 4. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400-408, 2008.

5. 5. Taniguchi H, Ebina M, Kondoh Y, et al; the Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829, 2010.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic effects of MEL-dKLA by targeting M2 macrophages in pulmonary fibrosis;Biomedicine & Pharmacotherapy;2024-09

2. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-07-04

3. Prognostic model of fibroblasts in idiopathic pulmonary fibrosis by combined bulk and single-cell RNA-sequencing;Heliyon;2024-07

4. Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway;Biochemical Pharmacology;2024-07

5. Challenges in the management of idiopathic pulmonary fibrosis from a low- and middle-income country;Journal of the Pakistan Medical Association;2024-05-24